Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allergovit Grasses
- Development stage
- Phase 4
- Lead developer
- Allergopharma
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Allergovit Grasses is a subcutaneous allergoid immunotherapy (SCIT) developed by Allergopharma for the treatment of IgE-mediated allergic rhinitis, allergic rhinoconjunctivitis, and bronchial asthma caused by grass pollen sensitization. The product consists of a 100% mixture of chemically formaldehyde-modified allergoids derived from six grass species: *Holcus lanatus*, *Dactylis glomerata*, *Lolium perenne*, *Phleum pratense*, *Poa pratensis*, and *Festuca pratensis*. These allergoids are co-precipitated with aluminium hydroxide, which acts as a depot adjuvant to enhance the immune response while reducing allergenicity. By desensitizing the immune system through regular subcutaneous injections prior to the pollen season, Allergovit Grasses reduces allergic symptoms and the need for symptomatic medication. It has been available in Europe since 1987 and has been studied in various uptitration schedules to optimize patient convenience and safety.
- Brand names
- AllergovitAllergovit 6-grassesAllergovit6-grassesAllergovit-6-grasses
- Other names
- 6-grasses allergoidgrass pollen allergoidformaldehyde-modified allergoids from 6 grass pollen species
02
Targets
TCR (T cell antigen receptor complex)BCR (Immunoglobulin G B Cell Receptor)MHC II (Major histocompatibility complex class II receptor)IgE (Immunoglobulin E)Dac g (Orchard grass pollen allergen)Festuca pratensis pollen allergen (Fes p)Phl p (Timothy grass pollen allergen)Poa p (Poa pratensis pollen allergen)
Beyond the preview
Go deeper on Allergovit Grasses.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allergovit Grasses.